Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence

  title={Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence},
  author={Konstantinos Hatzimouratidis},
  journal={Clinical Interventions in Aging},
  pages={403 - 414}
  • K. Hatzimouratidis
  • Published 1 December 2006
  • Medicine, Biology
  • Clinical Interventions in Aging
Erectile dysfunction (ED) is a highly prevalent disease associated with aging as well as with several risk factors including hypertension, heart disease, obesity, dyslipidemia, diabetes, hypogonadism, drugs-related, and pelvic surgery. Many of these factors are components of the metabolic syndrome, a multiplex risk factor for cardiovascular disease (CVD). ED shares common risk factors with CVD. Endothelial dysfunction seems to be the early underlying pathophysiology across both conditions. The… 

Figures and Tables from this paper

Treatment for Erectile Dysfunction in the Elderly Using Phosphodiesterase Type V Inhibitors
Oral phosphodiesterase type 5 (PDE5) inhibitor is recommended as the first-line treatment choice for ED and is the most popular form of treatment and there is, however, no evidence that treating ED in patients with cardiovascular diseases increases cardiac risk.
Current Perspectives on Pharmacotherapy Treatments for Erectile Dysfunction
As the world’s older population increases, it is estimated that the prevalence of ED will double from 152 million men in 1995 to 322 millionMen in 2025, indicating a dire need to reevaluate current ED therapeutic strategies.
Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
The main clinical, cultural, and demographical factors to be considered for the treatment of ED have been identified and simple algorithms prepared should be a useful tool to be used in daily practice, which may help in choosing the right treatment for each subject affected by ED.
Erectile dysfunction in stroke patients: a multifactorial problem with important psychosocial consequences
Couning stroke survivors (in particular) for ED problems may be a demanding task; however, this is necessary to improve their quality of life.
Erectile Dysfunction in Individuals with Type 1 Diabetes is Associated with Long-term Metabolic Control and Diabetic Complications: A Cross-Sectional Study
The presence of ED in individuals with T1DM is associated with HbA1c, the presence of at least one diabetic complication, and skin AF, which is a marker of long-term glycemia control.
Menthol for the Treatment of Erectile Dysfunction: Generation and Technology Export
The use of menthol in the treatment of erectile dysfunction has been underexplored and is an opportunity for research and technological development based on a high innovation potential.
Oral Therapy for Erectile Dysfunction
As defined by the NIH, erectile dysfunction is the repeated inability to get an erection firm enough for sexual intercourse and the International Consultation on Sexual Medicine defined ED as the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual performance.


Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease.
This study showed that sildenafil was well tolerated in patients with CVD and ED, and was associated with significant increases in the mean end-of-treatment scores for the questions from the International Index of Erectile Function that assess the ability to achieve and maintain erections.
Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors.
Clinicians should be particularly careful to evaluate patients presenting with ED because the condition can be accompanied by a wide spectrum of risk factors requiring monitoring and treatment, and with adequate treatment and control of these risk factors, the use of sildenafil in a representative population of men with ED in a multispecialty clinic can achieve a higher efficacy rate than previous studies have indicated.
Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment.
This paper reviews the epidemiology of erectile dysfunction with an emphasis on the experience of older men, normal age related changes in the structure and function of the penis, how the accumulation of risk factors with age may contribute to the high prevalence of the disease in Older men, and established and emerging therapies.
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis.
All efficacy assessments indicated that sildenafil significantly improved erectile function both in elderly patients with ED of broad-spectrum etiology and in elderly Patients with ED and diabetes.
Sildenafil: a review of its use in erectile dysfunction.
Sildenafil was significantly more effective than placebo in erectile dysfunction of all tested causes and was significantly superior to placebo in improving erections and allowing successful penetrative sexual intercourse.
Prognostic Factors for Response to Sildenafil in Patients with Erectile Dysfunction
The basal severity of ED and etiological diagnosis are the prognostic factors most significantly associated with treatment outcome and sildenafil is a rather effective and well–tolerated treatment for ED.
Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial.
Treatment with sildenafil for ED was effective, resulting in an increased percentage of successful attempts at intercourse, and was well tolerated among men with type 1 diabetes.